The median overall survival for grade IV glioma patients with MGMT promoter-methylation was 57.1 (95% CI: 52.8–45.6) months compared to 50.2 (95% CI: 44.1–56.2) months in those without the mutation (p = 0.051). This evidence concerns the gene MGMT and central nervous system cancer.